tiprankstipranks
Trending News
More News >
Perspective Therapeutics (CATX)
:CATX

Perspective Therapeutics (CATX) AI Stock Analysis

Compare
1,361 Followers

Top Page

CA

Perspective Therapeutics

(NYSE MKT:CATX)

Rating:41Neutral
Price Target:
Perspective Therapeutics is facing severe operational challenges with no revenue and increasing net losses, which significantly impact its financial performance score. While the company's balance sheet shows some strength due to low leverage, the reliance on external financing raises sustainability concerns. The technical analysis indicates ongoing downward pressure, and the negative P/E ratio reflects severe valuation concerns. Overall, the stock's prospects are weak, requiring strategic turnaround efforts to improve its outlook.
Positive Factors
Clinical Efficacy
The presentation of preliminary data from the Pb-212-VMT-α-NET trial could indicate strong clinical activity comparable to impressive response rates seen in other trials.
Financial Stability
CATX reported a preliminary estimated unaudited cash position of approximately $227.8M, which is expected to fund operations into late 2026, indicating strong financial stability.
Safety Profile
The safety profile of VMT-α-NET continues to look promising with no dose-limiting toxicities, no Grade 4 or 5 treatment emergent adverse events, no discontinuations due to adverse events, no serious adverse events related to treatment, and only 24% of patients experienced a Grade 3 treatment emergent adverse event.
Negative Factors
Efficacy Concerns
Concerns over potential reduced efficacy compared to a competitor may be assuaged as the improvement in patient response is noted.

Perspective Therapeutics (CATX) vs. SPDR S&P 500 ETF (SPY)

Perspective Therapeutics Business Overview & Revenue Model

Company DescriptionPerspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
How the Company Makes MoneyPerspective Therapeutics makes money primarily through the commercialization of its proprietary therapeutic solutions. The company generates revenue by licensing its technologies to pharmaceutical companies, receiving milestone payments and royalties from successful product developments. Additionally, Perspective Therapeutics may engage in strategic partnerships and collaborations with other biotech firms and research institutions to co-develop products, further expanding its revenue streams. The company may also earn income from government grants and subsidies aimed at fostering innovation in healthcare.

Perspective Therapeutics Financial Statement Overview

Summary
Perspective Therapeutics faces critical challenges with no revenue generation and increasing net losses. The company's strong equity base and low leverage offer some financial stability, but the dependency on external financing and poor cash flow metrics raise concerns about its sustainability. Immediate strategic adjustments are essential to improve revenue generation and operational efficiency.
Income Statement
25
Negative
Perspective Therapeutics shows significant challenges in its income statement. Revenue has declined to zero in the most recent year from $1.43 million the previous year, indicating severe operational challenges. The net loss has widened significantly, exacerbating concerns about profitability and sustainability. The EBIT margin has improved due to reduced negative EBIT, but this is overshadowed by the lack of revenue.
Balance Sheet
65
Positive
The balance sheet reflects a strong equity position with low debt levels, evidenced by a debt-to-equity ratio of approximately 0.01. The company maintains a high equity ratio, suggesting financial stability despite ongoing losses. However, the substantial net losses indicate that the company is heavily reliant on external financing, posing a risk to long-term viability.
Cash Flow
30
Negative
Cash flow analysis shows substantial negative free cash flow, reflecting significant cash burn. The large financing cash flow indicates reliance on external funding to support operations. The operating cash flow to net income ratio is negative, as is the free cash flow to net income ratio, demonstrating inefficiency in converting income into cash.
Breakdown
Dec 2024Dec 2023Dec 2022Jun 2022Jun 2021
Income StatementTotal Revenue
0.001.43M7.10M10.79M10.05M
Gross Profit
0.001.43M1.63M4.62M5.12M
EBIT
10.46M-40.94M-15.18M-7.39M-3.44M
EBITDA
10.46M-39.96M-14.84M-7.39M-3.43M
Net Income Common Stockholders
-79.28M-46.51M-14.67M-7.15M-3.19M
Balance SheetCash, Cash Equivalents and Short-Term Investments
226.92M9.24M43.76M55.89M63.83M
Total Assets
341.10M97.89M58.09M64.44M70.42M
Total Debt
2.38M2.55M0.00524.00K776.00K
Net Debt
-59.20M-6.69M-20.99M-55.37M-63.05M
Total Liabilities
50.43M22.71M3.45M3.16M3.01M
Stockholders Equity
290.67M75.18M54.64M61.28M67.41M
Cash FlowFree Cash Flow
-72.71M-37.98M-12.47M-7.98M-3.22M
Operating Cash Flow
-18.29M-36.91M-12.17M-7.71M-2.84M
Investing Cash Flow
-218.93M24.37M-57.68M-284.00K-410.00K
Financing Cash Flow
289.38M785.00K56.00K56.00K64.68M

Perspective Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.32
Price Trends
50DMA
2.35
Positive
100DMA
2.66
Positive
200DMA
6.16
Negative
Market Momentum
MACD
0.19
Negative
RSI
66.68
Neutral
STOCH
64.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CATX, the sentiment is Positive. The current price of 3.32 is above the 20-day moving average (MA) of 2.64, above the 50-day MA of 2.35, and below the 200-day MA of 6.16, indicating a neutral trend. The MACD of 0.19 indicates Negative momentum. The RSI at 66.68 is Neutral, neither overbought nor oversold. The STOCH value of 64.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CATX.

Perspective Therapeutics Risk Analysis

Perspective Therapeutics disclosed 55 risk factors in its most recent earnings report. Perspective Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We may not be successful in managing the build-out of our manufacturing facilities and associated costs or satisfying manufacturing-related regulatory requirements. Q3, 2024

Perspective Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$202.08M48.257.41%26.86%
58
Neutral
$248.88M-44.97%21.06%-99.70%
54
Neutral
$156.07M-304.05%28.24%-334.39%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
MYMYO
53
Neutral
$107.22M-35.68%69.17%39.01%
52
Neutral
$171.04M-76.01%25.62%11.86%
41
Neutral
$246.44M-32.92%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CATX
Perspective Therapeutics
3.32
-9.68
-74.46%
MYO
Myomo
2.98
-0.42
-12.35%
BWAY
Brainsway
10.45
3.79
56.91%
LNSR
LENSAR
13.11
8.40
178.34%
MASS
908 Devices
6.94
0.73
11.76%
CVRX
CVRx
6.56
-2.57
-28.15%

Perspective Therapeutics Corporate Events

Executive/Board Changes
Perspective Therapeutics Appoints New Chief Financial Officer
Positive
Jan 6, 2025

Perspective Therapeutics has appointed Juan Graham as the new Chief Financial Officer, succeeding Jonathan Hunt who remains as Chief Accounting Officer. With nearly 25 years of experience in biopharmaceutical financial management, Graham’s expertise is expected to enhance the company’s strategic financial operations and support its growth, particularly as it advances its clinical programs and builds manufacturing infrastructure.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.